Proteolysis of α‐synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology
Open Access
- 18 July 2016
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 140 (4) , 662-678
Abstract
Progression of α‐synuclein inclusion pathology may occur through cycles of release and uptake of α‐synuclein aggregates, which induce additional intracellular α‐synuclein inclusion pathology. This process may explain (i) the presence of α‐synuclein inclusion pathology in grafted cells in human brains, and (ii) the slowly progressive nature of most human α‐synucleinopathies. It also provides a rationale for therapeutic targeting of extracellular aggregates to limit pathology spread. We investigated the cellular mechanisms underlying intraneuronal α‐synuclein aggregation following exposure to exogenous preformed α‐synuclein amyloid fibrils. Exogenous α‐synuclein fibrils efficiently attached to cell membranes and were subsequently internalized and degraded within the endosomal/lysosomal system. However, internalized α‐synuclein amyloid fibrils can apparently overwhelm the endosomal/lysosomal machinery leading to the induction of intraneuronal α‐synuclein inclusions comprised of endogenous α‐synuclein. Furthermore, the efficiency of inclusion formation was relatively low in these studies compared to studies using primary neuronal‐glial cultures over‐expressing α‐synuclein. Our study indicates that under physiologic conditions, endosomal/lysosomal function acts as an endogenous barrier to the induction of α‐synuclein inclusion pathology, but when compromised, it may lower the threshold for pathology induction/transmission. image Cover Image for this issue: doi: 10.1111/jnc.13787.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (NS089622, NS071122)
- National Institutes of Health (OD020026)
- National Parkinson Foundation (NPF-UN203)
This publication has 72 references indexed in Scilit:
- Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studiesActa Neuropathologica, 2015
- Prion-like acceleration of a synucleinopathy in a transgenic mouse modelNeurobiology of Aging, 2012
- Molecular mechanisms of α-synuclein neurodegenerationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagationNature Medicine, 2008
- Assembly-dependent endocytosis and clearance of extracellular a-synucleinThe International Journal of Biochemistry & Cell Biology, 2008
- Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body DiseaseJournal of Biological Chemistry, 2006
- Dynasore, a Cell-Permeable Inhibitor of DynaminDevelopmental Cell, 2006
- Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseasesAnnals of Neurology, 2002
- Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.Proceedings of the National Academy of Sciences, 1988
- Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexusesActa Neuropathologica, 1988